Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Baliakas, P, Tesi, B, Wartiovaara-Kautto, U, Stray-Pedersen, AR, Friis, LS, Dybedal, I, Hovland, R, Jahnukainen, K, Raaschou-Jensen, K, Ljungman, P, Rustad, CF, Lautrup, CK, Kilpivaara, O, Kittang, AO, Grønbæk, K, Cammenga, J, Hellström-Lindberg, E & Andersen, MK 2019, 'Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up' HemaSphere, bind 3, nr. 6, s. e321. https://doi.org/10.1097/HS9.0000000000000321

APA

CBE

Baliakas P, Tesi B, Wartiovaara-Kautto U, Stray-Pedersen AR, Friis LS, Dybedal I, Hovland R, Jahnukainen K, Raaschou-Jensen K, Ljungman P, Rustad CF, Lautrup CK, Kilpivaara O, Kittang AO, Grønbæk K, Cammenga J, Hellström-Lindberg E, Andersen MK. 2019. Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. HemaSphere. 3(6):e321. https://doi.org/10.1097/HS9.0000000000000321

MLA

Vancouver

Author

Baliakas, Panagiotis ; Tesi, Bianca ; Wartiovaara-Kautto, Ulla ; Stray-Pedersen, Asbj Rg ; Friis, Lone Smidstrup ; Dybedal, Ingunn ; Hovland, Randi ; Jahnukainen, Kirsi ; Raaschou-Jensen, Klas ; Ljungman, Per ; Rustad, Cecilie F ; Lautrup, Charlotte K ; Kilpivaara, Outi ; Kittang, Astrid Olsnes ; Grønbæk, Kirsten ; Cammenga, Jörg ; Hellström-Lindberg, Eva ; Andersen, Mette K. / Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults : Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. I: HemaSphere. 2019 ; Bind 3, Nr. 6. s. e321.

Bibtex

@article{e33c093116b8427d9d65fde45c9a6fdf,
title = "Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up",
abstract = "Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health Organization (WHO) classification for MNs. Individuals with MNs due to germline predisposition exhibit increased risk for the development of MNs, mainly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Setting the diagnosis of MN with germline predisposition is of crucial clinical significance since it may tailor therapy, dictate the selection of donor for allogeneic hematopoietic stem cell transplantation (allo-HSCT), determine the conditioning regimen, enable relevant prophylactic measures and early intervention or contribute to avoid unnecessary or even harmful medication. Finally, it allows for genetic counseling and follow-up of at-risk family members. Identification of these patients in the clinical setting is challenging, as there is no consensus due to lack of evidence regarding the criteria defining the patients who should be tested for these conditions. In addition, even in cases with a strong suspicion of a MN with germline predisposition, no standard diagnostic algorithm is available. We present the first version of the Nordic recommendations for diagnostics, surveillance and management including considerations for allo-HSCT for patients and carriers of a germline mutation predisposing to the development of MNs.",
author = "Panagiotis Baliakas and Bianca Tesi and Ulla Wartiovaara-Kautto and Stray-Pedersen, {Asbj Rg} and Friis, {Lone Smidstrup} and Ingunn Dybedal and Randi Hovland and Kirsi Jahnukainen and Klas Raaschou-Jensen and Per Ljungman and Rustad, {Cecilie F} and Lautrup, {Charlotte K} and Outi Kilpivaara and Kittang, {Astrid Olsnes} and Kirsten Gr{\o}nb{\ae}k and J{\"o}rg Cammenga and Eva Hellstr{\"o}m-Lindberg and Andersen, {Mette K}",
note = "Copyright {\circledC} 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.",
year = "2019",
month = "12",
doi = "10.1097/HS9.0000000000000321",
language = "English",
volume = "3",
pages = "e321",
journal = "HemaSphere",
issn = "2572-9241",
number = "6",

}

RIS

TY - JOUR

T1 - Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults

T2 - Recommendations for Genetic Diagnosis, Clinical Management and Follow-up

AU - Baliakas, Panagiotis

AU - Tesi, Bianca

AU - Wartiovaara-Kautto, Ulla

AU - Stray-Pedersen, Asbj Rg

AU - Friis, Lone Smidstrup

AU - Dybedal, Ingunn

AU - Hovland, Randi

AU - Jahnukainen, Kirsi

AU - Raaschou-Jensen, Klas

AU - Ljungman, Per

AU - Rustad, Cecilie F

AU - Lautrup, Charlotte K

AU - Kilpivaara, Outi

AU - Kittang, Astrid Olsnes

AU - Grønbæk, Kirsten

AU - Cammenga, Jörg

AU - Hellström-Lindberg, Eva

AU - Andersen, Mette K

N1 - Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

PY - 2019/12

Y1 - 2019/12

N2 - Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health Organization (WHO) classification for MNs. Individuals with MNs due to germline predisposition exhibit increased risk for the development of MNs, mainly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Setting the diagnosis of MN with germline predisposition is of crucial clinical significance since it may tailor therapy, dictate the selection of donor for allogeneic hematopoietic stem cell transplantation (allo-HSCT), determine the conditioning regimen, enable relevant prophylactic measures and early intervention or contribute to avoid unnecessary or even harmful medication. Finally, it allows for genetic counseling and follow-up of at-risk family members. Identification of these patients in the clinical setting is challenging, as there is no consensus due to lack of evidence regarding the criteria defining the patients who should be tested for these conditions. In addition, even in cases with a strong suspicion of a MN with germline predisposition, no standard diagnostic algorithm is available. We present the first version of the Nordic recommendations for diagnostics, surveillance and management including considerations for allo-HSCT for patients and carriers of a germline mutation predisposing to the development of MNs.

AB - Myeloid neoplasms (MNs) with germline predisposition have recently been recognized as novel entities in the latest World Health Organization (WHO) classification for MNs. Individuals with MNs due to germline predisposition exhibit increased risk for the development of MNs, mainly acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Setting the diagnosis of MN with germline predisposition is of crucial clinical significance since it may tailor therapy, dictate the selection of donor for allogeneic hematopoietic stem cell transplantation (allo-HSCT), determine the conditioning regimen, enable relevant prophylactic measures and early intervention or contribute to avoid unnecessary or even harmful medication. Finally, it allows for genetic counseling and follow-up of at-risk family members. Identification of these patients in the clinical setting is challenging, as there is no consensus due to lack of evidence regarding the criteria defining the patients who should be tested for these conditions. In addition, even in cases with a strong suspicion of a MN with germline predisposition, no standard diagnostic algorithm is available. We present the first version of the Nordic recommendations for diagnostics, surveillance and management including considerations for allo-HSCT for patients and carriers of a germline mutation predisposing to the development of MNs.

U2 - 10.1097/HS9.0000000000000321

DO - 10.1097/HS9.0000000000000321

M3 - Journal article

VL - 3

SP - e321

JO - HemaSphere

JF - HemaSphere

SN - 2572-9241

IS - 6

ER -

ID: 59261147